Clinical Trials

270 enrolled

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

NCT06305299 2026-04-14

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

27 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Recurrence

NCT06615479 2026-04-14

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

440 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT07257419 2026-04-13

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

60 enrolled

Recurrence, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02625480 2026-04-09

ZUMA-4

Phase 1/2 Completed

95 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Recurrence, Lymphoma, B-Cell

NCT07519187 2026-04-09

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

20 enrolled

Plasma cell

Recurrence, Neoplasms, Plasma Cell

NCT06986434 2026-04-08

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation

Phase EARLY_PHASE1 Not yet recruiting

20 enrolled

LymphoidPlasma cell

Lymphoma, Recurrence, Neoplasms, Plasma Cell

NCT01822652 2026-04-06

GRAIN

Phase 1 Active not recruiting

11 enrolled

CNS

Neuroblastoma, Recurrence

NCT03793478 2026-04-01

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Other hematologic neoplasm

65 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT07502287 2026-03-30

DUAL-NK-NB

36 enrolled

CNS

Neuroblastoma, Recurrence, Ganglioneuroblastoma

NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Phase 3 Withdrawn

Lymphoma, Follicular, Recurrence

NCT05537766 2026-03-10

ZUMA-25

Phase 2 Terminated

19 enrolled 28 charts

Burkitt Lymphoma, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Recurrence

NCT04416984 2026-03-04

ALPHA2

160 enrolled

Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03939026 2026-03-02

ALPHA

Phase 1 Completed

50 enrolled

Lymphoma, Lymphoma, Follicular, Recurrence

NCT05714345 2026-03-02

EXPAND

Phase 2 Terminated

2 enrolled 8 charts

Phase 1 Not yet recruiting

Lymphoma, Recurrence

NCT07428486 2026-02-23

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

24 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06096038 2026-02-20

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Phase 1 Active not recruiting

33 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasms, Recurrence

NCT06325748 2026-02-12

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

21 enrolled

MyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT06253663 2025-12-16

JKART-1

Phase 2 Active not recruiting

25 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT03573700 2025-11-18

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

24 enrolled 9 charts

Phase 2 Active not recruiting

Leukemia, Leukemia, Lymphoid, Recurrence, Leukemia, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04245839 2025-11-05

TRANSCEND FL

276 enrolled 5 FDA

Other hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03263936 2025-10-16

Epigenetic Reprogramming in Relapse/Refractory AML

Phase 1 Completed

37 enrolled 11 charts

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT04678336 2025-10-15

CD123 Redirected T Cells for AML in Pediatric Subjects

Phase 1 Terminated

12 enrolled

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT04697940 2025-09-19

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

33 enrolled

Recurrence, Lymphoma, B-Cell

NCT06347068 2025-09-16

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Phase 1 Enrolling by invitation

42 enrolled

Breast

Breast Neoplasms, Recurrence, Triple Negative Breast Neoplasms

NCT07168486 2025-09-11

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

15 enrolled

Lymphoma, Follicular, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05883449 2025-08-20

LuminICE-203

Phase 2 Terminated

25 enrolled 21 charts

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral

NCT05554939 2025-08-06

Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL

30 enrolled

Phase 1 Active not recruiting

Lymphoma, Non-Hodgkin, Recurrence

NCT04608487 2025-07-30

Axi-cel in CNS Lymphoma

18 enrolled

Lymphoma, Recurrence

NCT06838832 2025-07-30

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

30 enrolled

Recurrence

NCT05963217 2025-07-02

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

19 enrolled